Biodegradable polymer systems for the sustained release of polypeptides

Journal of Controlled Release

Volumn 13, Issue 2-3, 1990, Pages 279-294

  Hutchinson, F G ^a   Furr, B J A ^a  

^a AKZO NOBEL CENTRAL RESEARCH   (Netherlands)

Author keywords

biodegradable polymers; polypeptides, release mechanisms, polymer properties

Indexed keywords

DIMETHYLBENZ[A]ANTHRACENE; GOSERELIN; POLYGLACTIN; POLYGLYCOLIC ACID; POLYGLYCOLIDE; POLYLACTIC ACID; POLYLACTIDE; POLYMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; BIODEGRADATION; BREAST CANCER; CONFERENCE PAPER; DRUG DELIVERY SYSTEM; DRUG RELEASE; ESTRUS CYCLE; FEMALE; HISTOLOGY; HORMONE BLOOD LEVEL; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROSTATE CARCINOMA; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; SUSTAINED RELEASE PREPARATION; ULTRASTRUCTURE;

EID: 0025167027     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/0168-3659(90)90018-O     Document Type: Article

References (32)

1. Delivery systems of LHRH and analogs
2. Pharmaceutical approach to long-term therapy with peptides,
3. Buccal absorption of protirelin: an effective way to stimulate thyrotropin and prolactin
4. Vaginal absorption of a potent luteinizing hormone-releasing hormone analog (leuprolide) in rats. I. Absorption by various routes and absorption enhancement
5. Vaginal absorption of a potent luteinizing hormone-releasing hormone analog (leuprolide) in rats. II. Mechanism of absorption enhancement with organic acids
6. Vaginal absorption of a potent luteinizing hormone-releasing hormone analog (leuprolide) in rats. III. Effect of estrous cycle on vaginal absorption of hydrophilic model compounds
7. Vaginal absorption of a potent luteinizing hormone-releasing hormone analog (leuprolide) in rats. IV. Evaluation of the vaginal absorption and gonadotrophin response by radioimmunoassay
8. Lactic/glycolic acid polymers
9. Continuous release pharmaceutical compositions
10. Compatible polymers
11. Controlled release: mechanisms and rates
12. Pro-drug controlled release from polyglutamic acid
13. Use of synthetic polypeptides in the preparation of biodegradable delivery systems for narcotic antagonists
14. Polymers for the sustained release of macromolecules: their use in a single-step method of immunisation
15. The role of the fibrous capsule in the function of implanted drug-polymer sustained release systems
16. The design of controlled drug delivery systems based on biodegradable polymers
17. Biodegradable sustained release formulation of the LH-RH analogue 'Zoladex' for the treatment of hormone-responsive tumours
18. Results obtained in the treatment of prostate cancer patients with ‘Zoladex’
19. Testosterone and gonadotrophin profiles in patients on daily or monthly LHRH analogue ICI 118630 (‘Zoladex’) compared with orchiectomy
20. Laboratory models of hormone-dependent cancer
21. Characterisation of the Dunning R3327H prostatic adenocarcinoma: an appropriate model for prostatic cancer
22. Use of analogues of LHRH for treatment of cancer
23. Treatment of advanced prostate cancer with LHRH analogue ICI 118630: clinical response and hormonal mechanisms
24. Advanced carcinoma of the prostate: treatment with a GnRH agonist
25. Therapeutic potential of the LHRH agonist, ICI 118630, in the treatment of advanced prostatic carcinoma
26. Treatment of patients with advanced cancer of the prostate using a slow release (depot) formulation of the LHRH agonist ICI 118630
27. An LHRH analogue (‘Zoladex’) in the management of carcinoma of the prostate: a preliminary report comparing daily subcutaneous injection with monthly depot injections
28. Continuous subcutaneous administration of ‘Zoladex’ (ICI 118630 — an LH-RH analogue) to patients with advanced prostatic cancer
29. LHRH analogues in cancer treatment
30. The use of an LH-RH agonist (ICI 118630, ‘Zoladex’) in advanced premenopausal breast cancer